The first Takeda Anti-acid Optimization Management Summit Forum gathered strength and set sail together with all parties to explore acid suppression...

On May 15, the Takeda Anti-acid Optimization Management Summit Forum and the first anniversary celebration of the launch of voronola fumarate green films were grandly held in Tianjin.

Launching Ceremony of "Suppressing Acid Era, Woqi New Chapter"

In recent years, with changes in life>Taking the common reflux esophagitis (RE) as an example, the total number of patients is estimated to be as high as 89 million.

Chairman of the Chinese Medical Association Gastroenterology Branch, Professor Chen Minhu, the First Affiliated Hospital of Sun Yat-sen University

In this forum, experts in the digestive field from various parties discussed the current status of gastroesophageal reflux (GERD) acid suppression treatment including RE, and discussed the patient's disease dilemma and actual treatment needs.

Professor Wang Bangmao from the General Hospital of Tianjin Medical University said: “In recent years, the diagnosis and treatment of RE has made some progress, but it still faces many challenges, including insufficient acid suppression by existing drugs, unsatisfactory healing rate, and low patient compliance.

Professor Wang Bangmao, General Hospital of Tianjin Medical University

Focusing on the latest status of acid suppression therapy in China, exploring the optimal management plan for acid suppression therapy is the core topic of this forum.

Professor You Suning, the former president and editor-in-chief of the Journal of the Chinese Medical Association, said: "Despite the continuous development of current treatments, RE, as a chronic disease, is still a major problem in the digestive field.

Professor You Suning, Former President and Editor-in-Chief of Journal of Chinese Medical Association